Heron Therapeutics, Inc. (NASDAQ:HRTX – Get Free Report) was the target of a large increase in short interest during the month of January. As of January 15th, there was short interest totalling 21,520,000 shares, an increase of 6.5% from the December 31st total of 20,210,000 shares. Based on an average trading volume of 3,330,000 shares, […]
/PRNewswire/ Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the U.S. Food and Drug Administration.
On January 23, 2024, Heron Therapeutics announced the FDA had approved its sNDA for bupivacaine and meloxicam extended-release solution to expand the indication to include soft tissue and orthopedic surgical procedures, including procedures in which direct exposure to articular cartilage is avoided.
Heron Therapeutics, Inc. announced that the U.S. Food and Drug Administration has approved its supplemental New Drug Application for ZYNRELEF® extended-release solution to expand the indication.
Heron Therapeutics (HRTX) Announces FDA Approval of ZYNRELEF Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.